CR20210327A - Anticuerpos agonistas de flt3 y usos de estos - Google Patents

Anticuerpos agonistas de flt3 y usos de estos

Info

Publication number
CR20210327A
CR20210327A CR20210327A CR20210327A CR20210327A CR 20210327 A CR20210327 A CR 20210327A CR 20210327 A CR20210327 A CR 20210327A CR 20210327 A CR20210327 A CR 20210327A CR 20210327 A CR20210327 A CR 20210327A
Authority
CR
Costa Rica
Prior art keywords
agonist antibodies
flt3
flt3 agonist
agonistic antibodies
antibodies
Prior art date
Application number
CR20210327A
Other languages
English (en)
Inventor
Melissa Beilschmidt
Dorothea Maetzel
Johan Fransson
Phil Gobeil
Arif Jetha
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of CR20210327A publication Critical patent/CR20210327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se describen anticuerpos agonistas anti-FLT3. Tales anticuerpos agonistas son útiles para la expansión de células dendríticas y el tratamiento contra el cáncer.
CR20210327A 2018-12-18 2019-12-17 Anticuerpos agonistas de flt3 y usos de estos CR20210327A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862781213P 2018-12-18 2018-12-18
PCT/IB2019/001437 WO2020128638A1 (en) 2018-12-18 2019-12-17 Flt3 agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20210327A true CR20210327A (es) 2021-09-27

Family

ID=71101095

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210327A CR20210327A (es) 2018-12-18 2019-12-17 Anticuerpos agonistas de flt3 y usos de estos

Country Status (21)

Country Link
US (1) US20220025055A1 (es)
EP (1) EP3902836A4 (es)
JP (1) JP2022513961A (es)
KR (1) KR20210111785A (es)
CN (1) CN113544152A (es)
AU (1) AU2019404098A1 (es)
BR (1) BR112021010948A2 (es)
CA (1) CA3120063A1 (es)
CL (1) CL2021001312A1 (es)
CO (1) CO2021007689A2 (es)
CR (1) CR20210327A (es)
DO (1) DOP2021000114A (es)
EA (1) EA202191650A1 (es)
EC (1) ECSP21044672A (es)
IL (1) IL283922A (es)
JO (1) JOP20210151A1 (es)
MA (1) MA54614A (es)
MX (1) MX2021007339A (es)
PE (1) PE20211474A1 (es)
SG (1) SG11202104352XA (es)
WO (1) WO2020128638A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635388A (en) * 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
DE19727814C1 (de) * 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
AU2010288194B2 (en) * 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
ES2573642T3 (es) * 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
ES2884844T3 (es) * 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
TWI757499B (zh) * 2017-06-02 2022-03-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
KR20200014777A (ko) * 2017-06-02 2020-02-11 화이자 인코포레이티드 Flt3을 표적으로 하는 키메라 항원 수용체

Also Published As

Publication number Publication date
MX2021007339A (es) 2021-07-15
CN113544152A (zh) 2021-10-22
JP2022513961A (ja) 2022-02-09
PE20211474A1 (es) 2021-08-05
JOP20210151A1 (ar) 2023-01-30
US20220025055A1 (en) 2022-01-27
SG11202104352XA (en) 2021-05-28
IL283922A (en) 2021-07-29
CA3120063A1 (en) 2020-06-25
EA202191650A1 (ru) 2021-10-22
MA54614A (fr) 2022-03-30
KR20210111785A (ko) 2021-09-13
CO2021007689A2 (es) 2021-06-21
ECSP21044672A (es) 2021-09-30
AU2019404098A1 (en) 2021-05-27
EP3902836A4 (en) 2022-08-31
WO2020128638A8 (en) 2021-06-03
BR112021010948A2 (pt) 2021-08-31
WO2020128638A1 (en) 2020-06-25
CL2021001312A1 (es) 2022-01-07
DOP2021000114A (es) 2021-09-30
EP3902836A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12021550152A1 (en) Anti-cd112r compositions and methods
MY194619A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MY186334A (en) Anti-her2 antibodies and immunoconjugates
NZ731467A (en) Anti-tim3 antibodies and methods of use
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
NZ735778A (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
CR20200239A (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
PH12020551716A1 (en) Anti-ror antibody constructs
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2022003967A (es) Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).
MY197534A (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
AU201715153S (en) Ramp
MX2021007339A (es) Anticuerpos agonistas de flt3 y usos de estos.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.